Breaking News

Hikma Launches Dobutamine Injection, USP

U.S. portfolio of sterile injectable medicines exceeds 150 products spanning a wide range of therapeutic areas and dosage forms.

Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, launched Dobutamine Injection, USP, in a 250mg/20mL vial in the US. With this launch, Hikma’s U.S. portfolio of sterile injectable medicines now exceeds 150 products spanning a wide range of therapeutic areas and dosage forms. In addition, Hikma now markets approximately 30 sterile injectable medicines in Canada, with plans to launch up to 13 additional products this year. The company has also launched Hikma 503B, a new ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters